Abstract
In the beginning of the 1960’s inhibition of fat mobilizing lipolysis (FML) was introduced as a tool in experimental medicine and as a new principle in the treatment of certain metabolic disorders (1,2). There were two major reasons for this at that time. First, we had found that nicotinic acid has a very powerful pharmacological fat mobilizing lipolysis inhibitory (FMLI) property thereby reducing the levels of circulating plasma free fatty acids (FFA) (3,4). Secondly, models for the metabolic conseguences of excessive FFA mobilization were just being developed (Figure 1). These models predicted that excessive FFA mobilization might cause certain unwanted metabolic effects such as hyperlipidemia and ketosis. Therefore it became of clinical interest to consider the use of inhibitors of FFA mobilization in acute as well as chronic situations. Today these models are in principle still believed to be valid. The major causes and effects of excessive FFA mobilization are summarized in Tables 1 and 2. Some areas where the use of compounds with FMLI property might be of benefit are summarized in Table 3.
Keywords
- Free Fatty Acid
- Nicotinic Acid
- Free Fatty Acid Level
- Familial Hypercholesterolemia
- Plasma Free Fatty Acid
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
Carlson, L.A., Böberg, J. and Hogstedt, B. In: Handbook of Physiology. Adipose Tissue, A.E. Renold and C.F. Cahill, editors, 1965, pp. 625–644.
Carlson, L.A. Diabetologia 5: 361–365 (1969)
Carlson, L.A. and örö, L. Acta Med. Scand. 172: 641–645 (1962)
Carlson, L.A. Acta Med. Scand. 173: 719–722 (1963)
Carlson, L.A., Hedbom, Ch., Helgstrand, E., Sjoberg, B. and Stjernstrom, N.E. Drugs Affecting Lipid Metabolism, W.L. Holmes, L.A. Carlson, and R. Paoletti, editors. Plenum, New York, 1969, pp. 85–92.
Carlson, L.A., Hedbom, Ch., Helgstrapd, E., Misiorny, A., Sjoberg, B., Stjernstrom, N.E. and Westin, G. Acta Pharm. Suecia 9: 221–228 (1972)
Carlson, L.A., unpublished observations
Carlson, L.A., Walldius, G. and Butcher, R.W. Atherosclerosis 16: 349–357 (1972)
D’Costa, M.A. and Angel, A. J. Clin. Invest. 55 138–148 (1975)
Carlson, L.A. Proc. Roy. Soc. Med. 69: 101–103 (1976)
Kurien, V.A. and Oliver, M.F. Lancet 2: 122 (1966)
Oliver, M.F., Kurien, V.A. and Greenwood, T.W. Lancet 1.: 710 (1968)
Rowe, M.J., Neilson, J.M.M. and Oliver, M.F. Lancet 1: 295 (1975)
Challoner, D.R. and Steinberg, D. m. J. Physiol. 210; 280 (1966)
Havel, R.J., Carlson, L.A., Ekelund, L.-G. and Holmgren, A. Metabolism 13: 1402–1412 (1964)
Kjekshus, J.K. and Mjøs, O.D. J. Clin, invest 52. 1770 (1973)
Mjøs, O.D., Miller, N.E., Riemersma, R.A. and Oliver, M.F. Circulation 53 494–500 (1976)
Altschul, R., Hoffer, A. and Stephen, J.D. Arch. Biochem. 54: 558 (1955)
Niacin in vascular Disorders and Hyperlipemia, R. Altschul, Editor, Charles C. Thomas, Springfield, 1964.
Carlson, L.A. and Oro, L. Atherosclerosis 1–9 (1973) Niacin in Vascular Disorders and Hyper1ipemia, R. Altschul, editor, Charles C. Thomas, Springfield, 1964.
Carlson, L.A. In: Drugs Affecting Lipid Metabolism, W.L. Holmes, L.A. Carlson, and R. Paoletti, editors. Plenum, New York, 1969, pp. 3 27–338
Carlson, L.A., Froberg, S. and Oro, L. Atherosclerosis 16: 359–368 (1972)
Froberg, S.O., Böberg, J., Carlson, L.A. and Ericsson, M. In: Metabolic Effects of Nicotinic Acid and its Derivatives, K.F. Gey and L.A. Carlson, editors, Hans Huber Publisher, Bern, 1971, pp. 167–181
Barboriak, J.J. and Meade, R.C. Atherosclerosis 13: 199 (1971)
Carlson, L.A., Olsson, A.G., Oro, L., Rossner, S. and Walldius, G. In: Atherosclerosis III, G. Schettler and A. Weizel, editors, Springer-Verlag, Berlin, 1974, pp. 768–781
Carlson, L.A., Olsson, A.G. and Ballantyne, D. Atherosclerosis 26 603–609 (1977)
Metabolic Effects of Nicotinic Acid and its Derivatives, K.F. Gey and L.A. Carlson, Hans Huber Publisher, Bern, 1971
Schlierf, G. and Hess, G. Artery174–179 (1977)
Nikkilä, E.A. Metabolic Effects of Nicotinic Acid and Its Derivatives, K.F. Gey and L.A. Carlson, editors, Hans Huber Publisher, Bern, 1971, p. 487.
Otway, S., Robinson, D.C., Rogers, M.P. and Wing, D.R. In: Metabolic Effects of Nicotinic Acid and Its Derivatives, K.F. Gey and L.A. Carlson, editors, Hans Huber Publisher, Bern, 1971, p. 497
Shafrir, E. and Biale, Y. In: Metabolic Effects of Nicotinic Acid and Its Derivatives, K.F. Gey and L.A. Carlson, editors, Hans Huber Publisher, Bern, 1971, p. 515
Carlson, L.A., Eriksson, I. and Walldius, G. Acta Med. Scand. 194: 363–369 (1973)
Walldius, G. Acta Medica Scandinavica, Supplement 591(1976)
Carlson, L.A., Ekelund, L.-G and Oro, L. Acta Med. Scand. 183: 423–430 (1968)
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1978 Plenum Press, New York
About this chapter
Cite this chapter
Carlson, L.A. (1978). Nicotinic Acid and Inhibition of Fat Mobilizing Lipolysis. Present Status of Effects on Lipid Metabolism. In: Kritchevsky, D., Paoletti, R., Holmes, W.L. (eds) Drugs, Lipid Metabolism, and Atherosclerosis. Advances in Experimental Medicine and Biology, vol 109. Springer, Boston, MA. https://doi.org/10.1007/978-1-4684-0967-3_12
Download citation
DOI: https://doi.org/10.1007/978-1-4684-0967-3_12
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4684-0969-7
Online ISBN: 978-1-4684-0967-3
eBook Packages: Springer Book Archive